Is naltrexone suitable?
Current opioid use, recent opioid exposure, pregnancy, liver history, other medicines, and mental health can change the risk-benefit decision.
Evidence reviewed
Evidence review
The Sinclair Method
The Sinclair Method is a popular name for targeted naltrexone taken in relation to planned drinking. Trials support targeted dosing as a possible alcohol-reduction option for selected people, but the evidence does not justify a universal 78% success rate or a guaranteed extinction timeline.
Direct answer
Targeted naltrexone means taking prescribed naltrexone in anticipation of a higher-risk drinking situation rather than automatically taking it every day. The name “Sinclair Method” is widely used online, but it is not a separate medicine or a single globally standardised protocol.
Randomized trials have found benefit on some drinking outcomes in selected groups. They do not establish that 78% of everyone treated succeeds, that abstinence treatment fails 60–90% of the time, or that most people reach “extinction” within a fixed number of months. Daily naltrexone also has a substantial evidence base and remains the labelled or guideline-supported approach in many settings.
What the principal targeted-dosing trials show
| Study | Design | What it found | Important limit |
|---|---|---|---|
| Heinälä et al., 2001 | 121 people; naltrexone or placebo with coping-skills or supportive therapy | During 12 weeks of daily treatment, naltrexone plus coping skills reduced relapse to heavy drinking; a 20-week targeted phase followed | The often-repeated “78% success” claim is not the trial result |
| Santos et al., 2022 | 120 sexual and gender minority men with mild-to-moderate AUD; targeted 50 mg naltrexone or placebo for 12 weeks | Naltrexone reduced binge-drinking days and several secondary drinking outcomes | A specific population and short treatment period; not proof of the same effect for everyone |
Questions a clinician should resolve
Targeted dosing is a treatment decision, not a do-it-yourself drinking rule.
What is the actual goal?
Reduced heavy drinking, abstinence, craving, and treatment retention are different outcomes. Agree on measures and a review date.
Daily or targeted dosing?
The evidence and local product label may support different approaches. The plan should account for adherence and the likelihood of unplanned drinking.
What is the fallback plan?
Decide what happens after a missed dose, opioid pain emergency, worsening drinking, adverse effects, or no meaningful improvement.
Primary evidence
- Heinälä et al., 2001 randomized trial (PubMed)
Daily treatment followed by a targeted phase; 121 participants.
- Santos et al., 2022 randomized trial (PubMed)
Targeted oral naltrexone in 120 sexual and gender minority men.
- US naltrexone tablet prescribing information (DailyMed)
Contraindications and opioid-overdose warnings.
Discuss targeted naltrexone
Bring the trial links and your treatment goals to a licensed clinician. Ask how the evidence applies to you and how progress and safety will be monitored.